Search

Escalating concerns about CO2 emission from fossil fuel utilization and environmental pollution from fossil-derived plastic waste call for the sustainable production and utilization of renewable biodegradable plastic materials. Polyhydroxyalkanoates (PHAs) are biodegradable and biocompatible thermoplastics with thermal and mechanical properties comparable to conventional plastics; thus, they are promising materials to mitigate environmental pollution. (R)-3-Hydroxybutyrate (3HB), which is the most common building-block for PHAs, has the potential to be utilized in various medical applications and can also serve as a precursor to a variety of value-added stereospecific chemicals. In addition, it can be produced by microorganisms, such as engineered cyanobacteria, from inexpensive renewable resources such as waste CO2. However, higher titer and rate of (R)-3HB production by cyanobacteria beyond that found in the current literature are critical for commercial applications. Herein, we employed a facile strategy to identify the rate-limiting step in the photoautotrophic production of (R)-3HB by the cyanobacterium Synechocystis and found that acetoacetyl-CoA reductase activity is the bottleneck in the process. Optimization of the gene's ribosome binding site led to a 2.2-fold increase in enzyme activity. In the culture medium of the engineered organism, the (R)-3HB titer reached 1.84 g L−1 within 10 days, with a peak productivity of 263 mg L−1 day−1, using CO2 and light as the sole carbon and energy sources. Moreover, dramatic changes in carbon partition were discovered in the (R)-3HB-producing cells along the course of cultivation using 13C-metabolic flux analysis; after the rapid growth phase, a majority of carbon flux was redirected from the cell mass formation to the production of (R)-3HB in the engineered Synechocystis under the examined experimental conditions. [ABSTRACT FROM AUTHOR]

The correct structure of the symmetrical cyanobactin, ascidiacyclamide, was published in Chemical Communications by Hamamoto et al. in 1983. The cyanobactin family of compounds are cyclic peptides with modifications including azole/azoline rings, D-stereocentres and in some cases prenyl groups. Although related compounds were isolated earlier by Ireland et al., two of the three published structures later had to be corrected. Hamamoto's ascidiacyclamide structure assisted the understanding of the chemistry, bioactivity, biological origin and biosynthesis of this group of compounds. Cyanobactins are of interest as new chemotypes for the treatment of a range of diseases, in particular those in which extended binding sites are implicated. [ABSTRACT FROM AUTHOR]